Drug Profile
Ensifentrine - Verona Pharma
Alternative Names: RPL 554Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Verona Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Antifibrotics; Imines; Isoquinolines; Small molecules; Urea compounds
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Chronic obstructive pulmonary disease
- Phase II Asthma; Bronchiectasis; Cystic fibrosis
- Phase I Allergic asthma
- Discontinued Allergic rhinitis; COVID 2019 infections
Most Recent Events
- 29 Feb 2024 Verona Pharma with Nuance Pharma announces intention to launch nebulized ensifentrine for Chronic obstructive pulmonary disease in China, Hong Kong, Macau, Taiwan
- 11 Dec 2023 Phase-II clinical trials in Bronchiectasis (Inhalation) before December 2023 (Verona Pharma pipeline, December 2023)
- 09 Nov 2023 Verona Pharma plans a phase II trial for Bronchiectasis at unknown location (Inhalation)